These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28600037)

  • 1. Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.
    Wong CN; Wong CN; Liu FS
    Taiwan J Obstet Gynecol; 2017 Jun; 56(3):302-305. PubMed ID: 28600037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral cyclophosphamide in recurrent ovarian cancer.
    Handolias D; Quinn M; Foo S; Mileshkin L; Grant P; Dutu G; Rischin D
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e154-60. PubMed ID: 23718870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Gupta R; Cristea M; Frankel P; Ruel C; Chen C; Wang Y; Morgan R; Leong L; Chow W; Koczywas M; Koehler S; Lim D; Luu T; Martel C; McNamara M; Somlo G; Twardowski P; Yen Y; Idorenyi A; Raechelle T; Carroll M; Chung V
    Cancer Treat Res Commun; 2019; 21():100155. PubMed ID: 31279962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
    del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
    Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
    Martin JY; Urban RR; Liao JB; Goff BA
    J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study.
    Ferrandina G; Corrado G; Mascilini F; Malaguti P; Samaritani R; Distefano M; Masciullo V; Di Legge A; Savarese A; Scambia G
    BMC Cancer; 2014 Dec; 14():947. PubMed ID: 25495785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
    Tew WP; Sill MW; Walker JL; Secord AA; Bonebrake AJ; Schilder JM; Stuckey A; Rice L; Tewari KS; Aghajanian CA
    Gynecol Oncol; 2018 Nov; 151(2):257-263. PubMed ID: 30177462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
    Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD
    Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
    Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
    Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy.
    Gebbia V; Martorana F; Scandurra G; Valerio MR; Cufari S; Vigneri P; Sanò MV; Scollo P
    J Oncol Pharm Pract; 2024 Jul; 30(5):853-859. PubMed ID: 37501558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
    Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
    J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
    Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
    Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
    Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
    J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer.
    Cohen S; Schwartz M; Dottino P; Beddoe AM
    J Ovarian Res; 2019 Apr; 12(1):36. PubMed ID: 31027500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
    Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
    Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
    Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
    Kummar S; Oza AM; Fleming GF; Sullivan DM; Gandara DR; Naughton MJ; Villalona-Calero MA; Morgan RJ; Szabo PM; Youn A; Chen AP; Ji J; Allen DE; Lih CJ; Mehaffey MG; Walsh WD; McGregor PM; Steinberg SM; Williams PM; Kinders RJ; Conley BA; Simon RM; Doroshow JH
    Clin Cancer Res; 2015 Apr; 21(7):1574-82. PubMed ID: 25589624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer.
    Watanabe Y; Etoh T; Koike E; Mizuno Y; Wang WM; Hoshiai H
    Int J Clin Oncol; 2010 Oct; 15(5):468-71. PubMed ID: 20480200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
    Teneriello MG; Tseng PC; Crozier M; Encarnacion C; Hancock K; Messing MJ; Boehm KA; Williams A; Asmar L
    J Clin Oncol; 2009 Mar; 27(9):1426-31. PubMed ID: 19224848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.